Skip to Content

Join the 'Herpes Zoster - Prophylaxis' group to help and get support from people like you.

Herpes Zoster - Prophylaxis News

New Shingles Vaccine, Shingrix, Approved by FDA

Posted 25 Oct 2017 by

A new, more effective shingles vaccine has been approved by the U.S. Food and Drug Administration. The new vaccine from GlaxoSmithKline will be the second shingles vaccine available in the U.S. market. The other is from Merck and was introduced in 2006, the Associated Press reported. Shingles is a painful condition caused by the chickenpox virus. Anyone who's had chickenpox carries the virus that causes shingles. A study funded by Glaxo found that the company's Shingrix vaccine prevented shingles in about 90 percent of people. Merck's Zostavax vaccine is about 50 percent effective, the AP reported. Shingrix will cost $280 for the required two shots. Zostavax costs $223. Most insurance plans cover the vaccination. Both vaccines are for adults 50 and older, but the Centers for Disease Control and Prevention recommends vaccination for people 60 and older, partly because vaccination loses ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster Iridocyclitis, Shingrix, Herpes Zoster - Prophylaxis, Zoster Vaccine Live, Zoster Vaccine (recombinant), Herpes Zoster Meningitis, Herpes Zoster Myelitis, Herpes Zoster Peripheral Neuropathy

Experimental Shingles Vaccine Looks Quite Effective: Study

Posted 15 Sep 2016 by

WEDNESDAY, Sept. 14, 2016 – An experimental vaccine against shingles may offer lasting protection for most older adults who receive it, a new clinical trial found. Shingles is a painful rash that's triggered by a reactivation of the virus that causes chickenpox. About one-third of Americans develop the disease at some point, according to the U.S. Centers for Disease Control and Prevention (CDC). There already is a vaccine against shingles, but its effectiveness is limited. The new study found that the experimental vaccine protected about 90 percent of adults age 70 and up. And the effects were still apparent four years later. By comparison, the existing vaccine, Zostavax, cuts the risk of shingles by about half. And immunity wanes within five years, according to the CDC. The study results were published in the Sept. 15 issue of the New England Journal of Medicine. Researchers called ... Read more

Related support groups: Herpes Zoster, Zostavax, Varicella-Zoster, Zoster Vaccine Live, Vaccination and Prophlaxis, Herpes Zoster - Prophylaxis, Varicella-Zoster - Prophylaxis

Asthma May Be Linked to Shingles Risk

Posted 31 Dec 2015 by

THURSDAY, Dec. 31, 2015 – People who suffer from asthma may be more likely to develop the painful skin condition known as shingles, a new study suggests. The finding builds on previous research that suggested a link between childhood asthma and shingles risk. "Asthma represents one of the five most burdensome chronic diseases in the U.S., affecting up to 17 percent of the population," said study author Dr. Young Juhn, a general academic pediatrician and asthma epidemiologist at the Mayo Clinic Children's Research Center in Rochester, Minn. "The effect of asthma on the risk of infection or immune dysfunction might very well go beyond the airways," Juhn said in a Mayo news release. The researchers analyzed the medical records of patients with suspected cases of shingles. They identified 371 people (average age 67) with the condition. Those patients were compared to 742 people who didn't ... Read more

Related support groups: Asthma, Herpes Zoster, Asthma - Maintenance, Asthma - Acute, Zostavax, Allergic Asthma, Herpes Zoster - Prophylaxis, Reversible Airways Disease, Reversible Airways Disease - Maintenance

Start of School Year Calls for Vaccine Check

Posted 21 Aug 2015 by

FRIDAY, Aug. 21, 2015 – With the start of a new school year, many parents are searching for vaccination records and hoping they're current, but what does "up-to-date" look like these days? That depends on whether it's what the school requires or what pediatric experts recommend. "Not all vaccines that we recommend on the schedule are required by schools," said Wendy Sue Swanson, a pediatrician at Seattle Children's Hospital. "But schools help us keep up-to-date and have an annual assessment" of vaccine status. Swanson explained that during childhood, three key school transitions coincide with vaccine schedules. The first, she said, is when a child enters kindergarten. Then, "typically, at sixth grade, we refresh again. And there are updates that we provide kids at the end of high school as get they ready to go to college," she added. Each of these turning points usually means exposure ... Read more

Related support groups: BCG, Yellow Fever Vaccine, Prevnar 13, Zostavax, Prevnar, Gardasil, Typhoid Vaccine, Live, Vivotif Berna, Tetanus Toxoid, Rabies Vaccine, Human Diploid Cell, Hepatitis B Adult Vaccine, Varicella Virus Vaccine, Human Papillomavirus Vaccine, Pneumovax 23, Twinrix, Hepatitis B Prevention, Pneumococcal 23-polyvalent Vaccine, Vivotif Berna Vaccine, Rubella Virus Vaccine, FluLaval

Infectious-Disease Expert Debunks Common Vaccine Myths

Posted 12 May 2015 by

TUESDAY, May 12, 2015 – A small minority of people still distrust the safety of routine childhood vaccinations, but one expert says the myths that swirl around vaccines are easily dismissed. "Both parents and doctors have the same goal, to keep a child healthy, and the best way to keep a child safe is through vaccination," said Dr. Nadia Qureshi, a pediatric infectious disease specialist at Loyola University Health System in Chicago. According to the U.S. Centers for Disease Control and Prevention, vaccines have saved more than 732,000 lives in the United States over the past two decades. But misconceptions about these simple but crucial health care interventions persist. One major myth is that the measles-mumps-rubella (MMR) vaccine causes autism, said Qureshi, who is also an assistant professor of pediatrics at Loyola University. "This myth began in 1998 when an English surgeon ... Read more

Related support groups: Autism, Measles, Hepatitis B Prevention, Pneumococcal Disease Prophylaxis, Tetanus Prophylaxis, Human Papillomavirus Prophylaxis, Influenza Prophylaxis, Pneumocystis Pneumonia Prophylaxis, Poliomyelitis Prophylaxis, Hepatitis B Prophylaxis, Vaccination and Prophlaxis, Herpes Zoster - Prophylaxis, Rubella Prophylaxis, Measles Prophylaxis, Diphtheria Prophylaxis, Haemophilus influenzae Prophylaxis, Meningococcal Meningitis Prophylaxis, Hepatitis A Prophylaxis, Mumps Prophylaxis, Pertussis Prophylaxis

Shingles Vaccine Still Effective After Chemotherapy

Posted 8 Aug 2014 by

FRIDAY, Aug. 8, 2014 – The shingles vaccine remains effective in older people after they've had chemotherapy, a new study finds. "The zoster vaccine (Zostavax) has been shown to be safe and effective in elderly adults with healthy immune systems but until now, there has been a lack of data on whether the vaccine remains safe and effective for individuals who might have compromised immune systems resulting from treatments like chemotherapy," study author Hung Fu Tseng, of the Kaiser Permanente Southern California Department of Research and Evaluation, said in a Kaiser news release. "Our study demonstrates that older patients who had previously been vaccinated against shingles have a lower chance of developing this painful and often debilitating disease after chemotherapy," Tseng said. Researchers analyzed the medical records of more than 21,000 people aged 60 and older who had ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster - Prophylaxis, Zoster Vaccine Live

Few U.S. Seniors Take Advantage of Shingles Vaccine

Posted 9 Apr 2013 by

TUESDAY, April 9 – The shingles vaccine is effective but few American seniors get it, according to a new study. Shingles is a painful skin and nerve infection that occurs when the chickenpox virus is reactivated in older adults who had chickenpox as children. The vaccine helps prevent reactivation of the virus. Researchers led by Sinead Langan from the London School of Hygiene and Tropical Medicine examined data collected from more than 766,000 Medicare beneficiaries between 2007 and 2009, and found that the vaccine reduced the rate of shingles by 48 percent overall. However, the vaccine was less effective in seniors with weakened immune systems, according to the report published April 9 in the journal PLoS Medicine. The vaccine reduced the rate of a painful shingles-related complication called post-herpetic neuralgia by 59 percent, the investigators found. Despite its effectiveness, ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster - Prophylaxis, Zoster Vaccine Live

Shingles Vaccine Safe, Underutilized, Study Says

Posted 23 Apr 2012 by

MONDAY, April 23 – The shingles vaccine is generally safe and well tolerated by patients, according to a new study. Shingles, which affects more than 1 million people each year in the United States, is a painful contagious rash caused by the dormant chickenpox virus, which can reactivate and replicate, damaging the nervous system. Elderly people are especially at risk because immunity against the virus that causes shingles declines with age. In this study, researchers looked at data from more than 193,000 adults 50 and older who received the shingles vaccine, also known as the herpes zoster vaccine, over two years. There was a small increased risk of local reactions (redness and pain) from one to seven days after vaccination. This finding matches the results of clinical trials. The shingles vaccine did not increase the risk for cerebrovascular diseases; cardiovascular diseases; ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster - Prophylaxis, Zoster Vaccine Live

Fear Proves Prime Motivator for Vaccinations

Posted 16 Sep 2011 by

FRIDAY, Sept. 16 – Sometimes a little fear might be a good thing. To run an effective public vaccination program, you've got to make sure that adequate amounts of the vaccine are available and there are enough staff members to administer it, said Dr. Adewale Troutman, director of the public health practice program at the University of South Florida, who, until recently, headed the Department of Public Health and Wellness in Louisville. You also have to figure out when the public will be available to come get the vaccinations you offer. And, of course, you need to make sure they are properly frightened. Fear has proven to be the most potent motivator in getting people to not shrug off important immunizations, like an annual flu shot, Troutman said. "The influenza vaccine is really an important immunization that people discount because, ehh, it's just the flu," he said. "But tens of ... Read more

Related support groups: Influenza, Herpes Zoster, Zostavax, Swine Influenza, FluLaval, FluMist, Influenza Prophylaxis, Fluzone, Afluria, Herpes Zoster - Prophylaxis, Influenza Virus Vaccine, Inactivated, Zoster Vaccine Live, Fluzone WV, Fluogen, Fluvirin, Fluzone PFS, Fluarix, Fluzone SV, Flushield, Agriflu

U.S. Shingles Vaccine Approval Expanded

Posted 26 Mar 2011 by

THURSDAY, March 24 – The Zostavax shingles vaccine is now approved by the U.S. Food and Drug Administration for people aged 50 and older. FDA-sanctioned use of the vaccine, first approved in 2006, had been limited to people 60 and older. The expanded approval includes the about 200,000 people aged 50 to 59 who contract shingles each year, the agency said in a news release. Shingles is caused by the same varicella-zoster virus that caused chickenpox when the affected people were younger. The virus lies dormant in the body until years later, when for reasons that aren't understood, it re-emerges as shingles – commonly in older people with weakened immune systems. Shingles is characterized by a painful blistery rash, often on one side of the body. In some people, the severe pain can last for months or years after shingles emerges, the FDA said. The vaccine was clinically evaluated in ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster - Prophylaxis

Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease

Posted 12 Jan 2011 by

Kaiser Permanente Research Strengthens National Recommendations PASADENA, Calif., Jan. 11, 2011 /PRNewswire/ – Receiving the herpes zoster vaccine was associated with a 55 percent reduced risk of developing shingles, according to a Kaiser Permanente study of 300,000 people that appears in the current issue of the Journal of the American Medical Association. This retrospective study observed the outcomes of the effectiveness of the herpes zoster vaccine in a large, diverse population of men and women ages 60 years and older. Researchers found a significant reduced risk of shingles across all sub-groups – those who are healthy as well as those with chronic conditions including diabetes or heart, lung or kidney diseases. These study findings differ from the clinical trial of the vaccine, which observed its effectiveness on 38,000 participants 60 years of age and older and found it less ... Read more

Related support groups: Zostavax, Herpes Zoster - Prophylaxis

Shingles Vaccine Looks Like a Safe Bet for Seniors: Study

Posted 11 Jan 2011 by

TUESDAY, Jan. 11 – Jane Adrian, 61, a landscape architect in Glendale, Calif., saw her parents and two co-workers suffer from the painful, blistering condition known as shingles, so when the vaccine became available, she got it. Even though the vaccine is only about 55 percent effective, "it's better than nothing," she said. "Now I feel relieved." A study of a cross-section of adults enrolled with a health-management organization in southern California shows that the vaccine provides protection for many older adults without many side effects. The findings are published in the Jan. 12 issue of the Journal of the American Medical Association. Shingles is caused by the herpes zoster virus and only strikes people who have had chicken pox. It usually starts as a rash on one side of the face or body, often causing pain, itching and tingling. About a million cases occur in the United States ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster - Prophylaxis

Ask a Question

Further Information

Related Condition Support Groups

Vaccination and Prophlaxis

Related Drug Support Groups

Zostavax, Shingrix, zoster vaccine live, zoster vaccine (recombinant)